Page 81 - Read Online

Page 16 of 17 Stojkovska Docevska et al. Rare Dis Orphan Drugs J 2023;2:14 https://dx.doi.org/10.20517/rdodj.2023.09

103. Doyle K, Lönn H, Käck H, et al. Discovery of second generation reversible covalent DPP1 inhibitors leading to an oxazepane
amidoacetonitrile based clinical candidate (AZD7986). J Med Chem 2016;59:9457-72. DOI
104. Palmér R, Mäenpää J, Jauhiainen A, et al. Dipeptidyl peptidase 1 inhibitor AZD7986 induces a sustained, exposure-dependent
reduction in neutrophil elastase activity in healthy subjects. Clin Pharmacol Ther 2018;104:1155-64. DOI PubMed PMC
105. Chalmers JD, Haworth CS, Metersky ML, et al; WILLOW Investigators. Phase 2 trial of the DPP-1 inhibitor brensocatib in
bronchiectasis. N Engl J Med 2020;383:2127-37. DOI
106. Sinha S, Rosin NL, Arora R, et al. Dexamethasone modulates immature neutrophils and interferon programming in severe COVID-
19. Nat Med 2022;28:201-11. DOI PubMed PMC
107. Seren S, Derian L, Keleş I, et al. Proteinase release from activated neutrophils in mechanically ventilated patients with non-COVID-
19 and COVID-19 pneumonia. Eur Respir J 2021;57:2003755. DOI PubMed PMC
108. Keir HR, Long MB, Abo-Leyah H, et al; STOP-COVID19 Investigators. Dipeptidyl peptidase-1 inhibition in patients hospitalised
with COVID-19: a multicentre, double-blind, randomised, parallel-group, placebo-controlled trial. Lancet Respir Med 2022;10:1119-
28. DOI PubMed PMC
109. Korkmaz B, Lesner A, Wysocka M, et al. Structure-based design and in vivo anti-arthritic activity evaluation of a potent dipeptidyl
cyclopropyl nitrile inhibitor of cathepsin C. Biochem Pharmacol 2019;164:349-67. DOI
110. Rehm SRT, Smirnova NF, Morrone C, et al. Premedication with a cathepsin C inhibitor alleviates early primary graft dysfunction in
mouse recipients after lung transplantation. Sci Rep 2019;9:9925. DOI PubMed PMC
111. Miller BE, Mayer RJ, Goyal N, et al. Epithelial desquamation observed in a phase I study of an oral cathepsin C inhibitor
(GSK2793660). Br J Clin Pharmacol 2017;83:2813-20. DOI PubMed PMC
112. Badorrek P, Diefenbach C, Kögler H, et al. Phase I characterization of the novel cathepsin C inhibitor BI 1291583. Am J Resp Crit
Care 2022;205:A4777. DOI
113. Pettersen EF, Goddard TD, Huang CC, et al. UCSF Chimera-a visualization system for exploratory research and analysis. J Comput
Chem 2004;25:1605-12. DOI PubMed
114. Shen XB, Chen X, Zhang ZY, Wu FF, Liu XH. Cathepsin C inhibitors as anti-inflammatory drug discovery: challenges and
opportunities. Eur J Med Chem 2021;225:113818. DOI
115. Chen X, Yan Y, Zhang Z, et al. Discovery and in vivo anti-inflammatory activity evaluation of a novel non-peptidyl non-covalent
cathepsin C inhibitor. J Med Chem 2021;64:11857-85. DOI
116. Chen X, Yan Y, Du J, et al. Non-peptidyl non-covalent cathepsin C inhibitoEEr bearing a unique thiophene-substituted pyridine:
design, structure-activity relationship and anti-inflammatory activity in vivo. Eur J Med Chem 2022;236:114368. DOI PubMed
117. Radzey H, Rethmeier M, Klimpel D, Grundhuber M, Sommerhoff CP, Schaschke N. E-64c-hydrazide: a lead structure for the
development of irreversible cathepsin C inhibitors. ChemMedChem 2013;8:1314-21. DOI PubMed
118. Zhang R, Durkin JP, Windsor WT. Azapeptides as inhibitors of the hepatitis C virus NS3 serine protease. Bioorg Med Chem Lett
2002;12:1005-8. DOI PubMed
119. Venkatraman S, Kong J, Nimkar S, Wang QM, Aubé J, Hanzlik RP. Design, synthesis, and evaluation of azapeptides as substrates
and inhibitors for human rhinovirus 3C protease. Bioorg Med Chem Lett 1999;9:577-80. DOI PubMed
120. Verhelst SH, Witte MD, Arastu-Kapur S, Fonovic M, Bogyo M. Novel aza peptide inhibitors and active-site probes of papain-family
cysteine proteases. Chembiochem 2006;7:943-50. DOI PubMed
121. Bondebjerg J, Fuglsang H, Valeur KR, et al. Novel semicarbazide-derived inhibitors of human dipeptidyl peptidase I (hDPPI). Bioorg
Med Chem 2005;13:4408-24. DOI
122. Drąg M, Wieczerzak E, Pawełczak M, Berlicki Ł, Grzonka Z, Kafarski P. Toward very potent, non-covalent organophosphonate
inhibitors of cathepsin C and related enzymes by 2-amino-1-hydroxy-alkanephosphonates dipeptides. Biochimie 2013;95:1640-9.
DOI PubMed
123. Jewgiński MP, Makowski M, Pawełczak M, et al. Synthesis of hybrid tripeptide peptidomimetics containing dehydroamino acid and
aminophosphonic acid in the chain and evaluation of their activity toward cathepsin C. Chem Biodivers 2022;19:e202101019. DOI
124. Sun H, Ren Y, Hou W, et al. Focusing on probe-modified peptides: a quick and effective method for target identification. Chem
Commun 2016;52:10225-8. DOI
125. Hou W, Sun H, Ma Y, Liu C, Zhang Z. Identification and optimization of novel cathepsin C inhibitors derived from EGFR inhibitors.
J Med Chem 2019;62:5901-19. DOI PubMed
126. Wang J, Chu Y, Zhou X. Inhibitory effect of triperygium wilfordii polyglucoside on dipeptidyl peptidase I in vivo and in vitro.
Biomed Pharmacother 2017;96:466-70. DOI PubMed
127. Ulčakar L, Novinec M. Inhibition of human cathepsins B and L by caffeic acid and its derivatives. Biomolecules 2020;11:31. DOI
PubMed PMC
128. Touaibia M, Jean-François J, Doiron J. Caffeic acid, a versatile pharmacophore: an overview. Mini Rev Med Chem 2011;11:695-713.
DOI PubMed
129. Novinec M, Lenarčič B, Baici A. Probing the activity modification space of the cysteine peptidase cathepsin K with novel allosteric
modifiers. PLoS One 2014;9:e106642. DOI PubMed PMC
130. Changeux JP, Christopoulos A. Allosteric modulation as a unifying mechanism for receptor function and regulation. Cell
2016;166:1084-102. DOI PubMed